Amlodipine for coronary artery disease
Pro Research Analysisby 
Searched over 200M research papers
Amlodipine and Coronary Artery Disease: Mechanisms and Clinical Benefits
Amlodipine, a third-generation dihydropyridine calcium channel blocker, is widely used in the management of coronary artery disease (CAD) due to its vascular selectivity, long half-life, and favorable safety profile. Its role in CAD extends beyond blood pressure control, offering additional cardiovascular benefits .
Plaque Stabilization and Antiatherogenic Effects of Amlodipine
Research has shown that amlodipine may help stabilize atherosclerotic plaques, which are central to the development and progression of CAD. Clinical trials such as the PREVENT and CAPARES studies demonstrated that amlodipine treatment in patients with documented CAD led to significant reductions in cardiovascular events and slowed the progression of carotid atherosclerosis, independent of its blood pressure-lowering effects. These findings suggest that amlodipine may have direct vascular protective properties, potentially working synergistically with other treatments like statins to improve outcomes in CAD patients 17.
Symptom Relief and Improved Exercise Tolerance
Amlodipine has been shown to significantly reduce the frequency of angina attacks and the need for nitroglycerin in patients with severe CAD. It also improves exercise tolerance, as evidenced by increased time to onset of angina and reduced ST-segment depression during exercise testing. These benefits are achieved without significant adverse effects on heart rate or serious side effects, making amlodipine a safe option for symptom management in CAD 25.
Hemodynamic Improvements and Cardiac Function
Studies indicate that amlodipine reduces systemic arterial blood pressure and vascular resistance, while increasing cardiac output and stroke volume. It also lowers left ventricular afterload and filling pressures, which can improve cardiac pumping performance in patients with stable CAD. These hemodynamic changes contribute to better overall cardiac function and may help prevent the progression of heart failure in this population 68.
Prevention of Graft Coronary Artery Disease
Experimental models have shown that amlodipine can suppress the development of graft coronary artery disease in transplanted hearts, suggesting a potential role for calcium channel blockers in preventing vascular complications after heart transplantation .
Combination Therapy: Perindopril and Amlodipine
Combining amlodipine with the ACE inhibitor perindopril has demonstrated additional benefits in patients with stable CAD and hypertension. This fixed-dose combination not only lowers blood pressure more effectively but also improves exercise capacity and angina class, with favorable effects on cardiovascular risk factors and metabolic profiles. The combination is associated with improved cardiovascular outcomes and simplified management for patients with both hypertension and CAD 910.
Cost-Effectiveness of Amlodipine in CAD Management
Economic analyses reveal that amlodipine therapy in CAD patients leads to fewer hospitalizations for angina, heart failure, and myocardial infarction, resulting in improved clinical outcomes and slight cost savings over a three-year period compared to placebo .
Conclusion
Amlodipine is an effective and well-tolerated option for patients with coronary artery disease. It not only controls blood pressure and relieves angina symptoms but also offers additional vascular protective effects, improves cardiac function, and is cost-effective. When used alone or in combination with other agents like perindopril, amlodipine plays a key role in optimizing the management and outcomes of patients with CAD 1235+5 MORE.
Sources and full results
Most relevant research papers on this topic